When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Today is like a little taste of what the year could be like if everything goes just right. Inflation is cooler, bond yields ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...